Sleep disorders

Inspire Medical Systems, Inc. Announces Second Quarter 2021 Financial Results and Updates 2021 Outlook

Retrieved on: 
Tuesday, August 3, 2021
Clinical medicine, Medicine, Sleep disorders, Branches of biology, Sleep apnea, Obstructive sleep apnea, Transoral robotic surgery

The webcast replay will be available on the Inspire website for two weeks following the completion of the call.

Key Points: 
  • The webcast replay will be available on the Inspire website for two weeks following the completion of the call.
  • Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea.
  • Inspires proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
  • These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release.

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda’s Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)

Retrieved on: 
Wednesday, July 28, 2021
Research, Medical Supplies, FDA, Genetics, Clinical trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Branches of biology, Sleep disorders, Molecular neuroscience, Neuropeptides, Neuroscience, Amphetamine, Narcolepsy, G protein-coupled receptors, Orexin, Cataplexy, Hypocretin (orexin) receptor 2, Danavorexton

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to TAK-994,1 its Phase 2 investigational oral orexin agonist, which is designed to selectively target orexin 2 receptors.

Key Points: 
  • Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to TAK-994,1 its Phase 2 investigational oral orexin agonist, which is designed to selectively target orexin 2 receptors.
  • Individuals with narcolepsy type 1 suffer from excessive daytime sleepiness, which might mean routinely falling asleep at work or in school.
  • This designation marks a key milestone in Takedas accelerated development efforts to bring this important potential therapy to patients with NT1.
  • A Study of TAK-994 in Participants With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 [NT1] or Narcolepsy Type 2 [NT2]).

Miami Periodontist Implements New Treatment for TMJ Disorders

Retrieved on: 
Wednesday, July 28, 2021
Anatomy, Musculoskeletal system, Branches of biology, Musculoskeletal disorders, Sleep disorders, Prosthodontology, Dentistry, Temporomandibular joint dysfunction, Dental equipment, Bruxism, Temporomandibular joint, Dental implant

MIAMI, July 28, 2021 /PRNewswire-PRWeb/ -- Miami Periodontist and Dental Implant Specialist Dr. John Paul Gallardo has announced a new method of treating TMJ disorder using laser therapy.

Key Points: 
  • MIAMI, July 28, 2021 /PRNewswire-PRWeb/ -- Miami Periodontist and Dental Implant Specialist Dr. John Paul Gallardo has announced a new method of treating TMJ disorder using laser therapy.
  • TMJ disorders include non alignment or injury to the teeth or jaw which limit the movement of the jaw joint and muscles around it.
  • TMJ disorders can be caused by teeth grinding or clenching, excessive chewing, and stress.
  • "There are several ways that doctors treat TMJ disorders whether it's with physical therapy or even surgery.

Itamar Medical to Report Second Quarter Financial Results and Host Conference Call on Tuesday, August 10, 2021

Retrieved on: 
Wednesday, July 28, 2021
Sleep disorders, Branches of biology, Itamar Medical, Sleep apnea, Apnea

The Company will host a conference call that day at 8:00 a.m. Eastern Time, 3:00 p.m. Israel Time to review financial results and provide a corporate update.

Key Points: 
  • The Company will host a conference call that day at 8:00 a.m. Eastern Time, 3:00 p.m. Israel Time to review financial results and provide a corporate update.
  • The call will be hosted by Gilad Glick, President and CEO, and Shy Basson, CFO.
  • Itamar Medical is a medical technology company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders.
  • Itamar Medical offers a Total Sleep Solution to help physicians provide comprehensive sleep apnea management in a variety of clinical environments to optimize patient care and reduce healthcare system costs.

Signifier Medical Technologies Raises $35M in Series D Funding Round to Accelerate Commercialization of eXciteOSA Therapy

Retrieved on: 
Tuesday, July 27, 2021
MEN, Research, Other Health, Professional services, Consumer, Venture capital, Medical devices, Science, Other Consumer, Women, Seniors, Health, Other Science, Health sciences, Life sciences, Therapy, Sleep disorders, Signifier Medical Technologies, eXciteOSA, Obstructive Sleep Apnea and Snoring, SIGNIFIER MEDICAL TECHNOLOGIES, EXCITEOSA, OBSTRUCTIVE SLEEP APNEA AND SNORING

Roger Gunnarsson, Managing Partner of Segulah Medical Acceleration, a fund which seeks to invest in and develop game changing businesses within medical technologies, said: Segulah Medical is delighted to be co-leading Signifier Medicals Series D financing.

Key Points: 
  • Roger Gunnarsson, Managing Partner of Segulah Medical Acceleration, a fund which seeks to invest in and develop game changing businesses within medical technologies, said: Segulah Medical is delighted to be co-leading Signifier Medicals Series D financing.
  • We are very excited about the prospects for eXciteOSA as a revolutionary daytime therapy to treat OSA.
  • Signifier Medical Technologies is a pioneer in understanding and addressing the root causes of sleep disordered breathing.
  • Founded in 2015, Signifier Medical Technologies is at the forefront of sleep therapy, focused on developing therapies that put patient experience and comfort first.

Top Sleep Experts Convene To Address CPAP Alternatives

Retrieved on: 
Tuesday, July 27, 2021
Sleep disorders, Medicine, Clinical medicine, Branches of biology, Continuous positive airway pressure, Mandibular advancement splint, Obstructive sleep apnea, Sleep apnea, Sleep Research Society, Osa, Sleep surgery

They will convene to discuss barriers and facilitators for adoption of non-PAP treatment approaches to obstructive sleep apnea (OSA), including Oral Appliance Therapy (OAT).

Key Points: 
  • They will convene to discuss barriers and facilitators for adoption of non-PAP treatment approaches to obstructive sleep apnea (OSA), including Oral Appliance Therapy (OAT).
  • The Sleep Research Society Foundation (SRSF) and SomnoMed put focus on non-CPAP alternatives in light of Philips recall.
  • "Our partnership with the Sleep Research Society will help bring these discussions to the forefront and treat more patients more effectively."
  • "This is a timely and important discussion about the true positioning of non-PAP treatment alternatives and the implementation aspects of such therapies," reflects Sairam Parthasarathy, MD, Board of Director, Sleep Research Society and President, Sleep Research Society Foundation.

David P. White, M.D. Appointed Senior Vice President of Medical Affairs at Apnimed

Retrieved on: 
Tuesday, July 27, 2021
Biotechnology, General Health, Medical devices, Health, Clinical trials, Sleep disorders, Branches of biology, Sleep apnea, Obstructive sleep apnea, Apnea, Sleep, Sleep medicine, International Classification of Sleep Disorders, Obstructive Sleep Apnea, Apnimed, OBSTRUCTIVE SLEEP APNEA, APNIMED

Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, today announced that David P. White, M.D., a world-renowned leader in sleep disorders has been appointed Senior Vice President of Medical Affairs.

Key Points: 
  • Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, today announced that David P. White, M.D., a world-renowned leader in sleep disorders has been appointed Senior Vice President of Medical Affairs.
  • Clinicians understand that obstructive sleep apnea is a prevalent and debilitating medical condition affecting the health and well-being of patients.
  • There is a tremendous unmet need for a safe, effective, and easy-to-use treatment option that addresses the underlying cause of the disease.
  • In addition to his new position at Apnimed, Dr. White is a Professor of Medicine, part-time, at Harvard Medical School in Boston, Mass.

Apria to Announce Second Quarter 2021 Financial Results

Retrieved on: 
Thursday, July 22, 2021
Sleep disorders, Branches of biology, Obstructive sleep apnea, Sleep apnea, Apnea, Lawrence Higby

INDIANAPOLIS, July 22, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the Company or Apria) (Nasdaq: APR) announced today that it will release fiscal second quarter 2021 financial results on Thursday, August 5, 2021 after the market closes.

Key Points: 
  • INDIANAPOLIS, July 22, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the Company or Apria) (Nasdaq: APR) announced today that it will release fiscal second quarter 2021 financial results on Thursday, August 5, 2021 after the market closes.
  • In conjunction, the company will host a conference call to review results at 5:00 p.m. (ET) on the same day.
  • Apria is a leading provider of integrated home healthcare equipment and related services in the United States, providing home respiratory therapy, obstructive sleep apnea treatment and negative pressure wound therapy.
  • Its approximately 275 locations throughout the continental United States and Hawaii serve nearly 2 million patients each year.

RareStone Inc. Announces Submission of New Drug Application (NDA) of Wakix® (pitolisant) for narcolepsy with and without cataplexy in China

Retrieved on: 
Wednesday, July 21, 2021
Sleep disorders, Psychoactive drugs, Orphan drugs, Drugs, Stimulants, Chloroarenes, Ethers, Pitolisant, Narcolepsy, Cataplexy, Obstructive sleep apnea, Idiopathic hypersomnia

Wakixwill be considered for approval in the treatment of narcolepsy with and without cataplexy in Greater China.

Key Points: 
  • Wakixwill be considered for approval in the treatment of narcolepsy with and without cataplexy in Greater China.
  • Through a partnership announced in Q4 2020 with Bioprojet, RareStone has exclusive rights for the commercialization and development of Wakixin China.
  • RareStone's lead product candidate, Wakix (pitolisant), is an investigational oral drug in development for the treatment of narcolepsy and obstructive sleep apnea in China.
  • Pitolisant has an orphan designation in the EU and the US for the treatment of narcolepsy.

Tired of the Grind, Americans Would Give Up a Promotion or Frequent Sex Just to Feel Well Rested

Retrieved on: 
Tuesday, July 20, 2021
Branches of biology, Mind, Self, Sleep disorders, Sleep, Somnolence, Irritability, Insomnia, Sleep deprivation

The study which explored Americans' health and wellness needs, goals and concerns, revealed that half (50%) consider improving their sleep as the top mental health goal in 2021.

Key Points: 
  • The study which explored Americans' health and wellness needs, goals and concerns, revealed that half (50%) consider improving their sleep as the top mental health goal in 2021.
  • "We often take sleepiness, irritability and the inability to focus as the totality of issues related to poor sleep.
  • These findings highlight the issue that Americans aren't getting quality sleepnot only are they having trouble falling asleep, but they're also facing issues staying asleep.
  • 1 in 4 Americans (24%) report they often wake up in the middle of the night and typically can't go back to sleep.